EVIDENCE THAT PRODUCTION OF INTERLEUKIN-6 WITHIN THE REJECTING ALLOGRAFT COINCIDES WITH CYTOTOXIC LYMPHOCYTE-T DEVELOPMENT

被引:35
作者
FORD, HR
HOFFMAN, RA
TWEARDY, DJ
KISPERT, P
WANG, S
SIMMONS, RL
机构
[1] UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261
[2] UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15261
[3] PITTSBURGH CANC INST,DEPT MED,PITTSBURGH,PA 15261
关键词
D O I
10.1097/00007890-199103000-00022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Current evidence suggests that the development of allosensitized cytotoxic T lymphocytes within sponge matrix allografts takes place primarily in situ and may be regulated by the secretory products of the cells infiltrating the graft. In vitro studies have implicated IL-2, IL-4, and IL-6 in CTL development. We have reported that TNF-alpha, macrophage colony-stimulating factor, IL-1, IFN-alpha, and IFN-beta are present in the allograft, but that IL-2 and IL-4 cannot be detected at any time using specific bioassays. In this study, we found significantly higher levels of IL-6 within the allografts compared with the syngeneic grafts. Peak IL-6 activity coincided with the appearance of allosensitized CTL in the allografts. IL-6 concentration in the serum of sponge allografted mice was less than 1% of that found in the graft. The sponge fluid exhibited both hybridoma growth factor and hepatocyte-stimulating factor activities in vitro, and both these activities were neutralized by antibody to murine IL-6 but not by antibody to murine IL-1-beta or TNF-alpha. Messenger RNA for murine IL-6 was detected in the graft-infiltrating cells. The high level of IL-6 found in the allograft coincident with the appearance of cellular immunity suggests that this cytokine might play some role in the development of allospecific CTL in vivo.
引用
收藏
页码:656 / 661
页数:6
相关论文
共 42 条
  • [1] PRODUCTION OF HYBRIDOMA GROWTH-FACTOR BY HUMAN-MONOCYTES
    AARDEN, LA
    DEGROOT, ER
    SCHAAP, OL
    LANSDORP, PM
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (10) : 1411 - 1416
  • [2] ASCHER NL, 1983, J IMMUNOL, V131, P617
  • [3] ASCHER NL, 1986, SURGERY, V100, P321
  • [4] BAUMANN H, 1987, J IMMUNOL, V139, P4122
  • [5] BAUMANN H, 1987, J BIOL CHEM, V262, P9756
  • [7] ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE
    CHIRGWIN, JM
    PRZYBYLA, AE
    MACDONALD, RJ
    RUTTER, WJ
    [J]. BIOCHEMISTRY, 1979, 18 (24) : 5294 - 5299
  • [8] GENOMIC SEQUENCING
    CHURCH, GM
    GILBERT, W
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07): : 1991 - 1995
  • [9] ELIAS JA, 1989, J IMMUNOL, V142, P509
  • [10] FONG YM, 1989, J IMMUNOL, V142, P2321